184 related articles for article (PubMed ID: 21524244)
1. Medical treatment of primary, secondary, and tertiary hyperparathyroidism.
Vestergaard P; Thomsen Sv
Curr Drug Saf; 2011 Apr; 6(2):108-13. PubMed ID: 21524244
[TBL] [Abstract][Full Text] [Related]
2. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
Drüeke TB; Ritz E
Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
4. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
Vestergaard P; Nielsen LR; Mosekilde L
Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
[TBL] [Abstract][Full Text] [Related]
5. [Clinical application of calcimimetics].
Nishi H; Fukagawa M
Clin Calcium; 2004 May; 14(5):756-9. PubMed ID: 15577038
[TBL] [Abstract][Full Text] [Related]
6. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
Finch JL; Tokumoto M; Nakamura H; Yao W; Shahnazari M; Lane N; Slatopolsky E
Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1315-22. PubMed ID: 20200094
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.
de Francisco AL
Expert Opin Pharmacother; 2005 Mar; 6(3):441-52. PubMed ID: 15794735
[TBL] [Abstract][Full Text] [Related]
8. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
[TBL] [Abstract][Full Text] [Related]
9. [Calcimimetics, mechanisms of action and therapeutic applications].
Ureña P; Legoupil N; de Vernejoul MC
Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
[TBL] [Abstract][Full Text] [Related]
10. Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient.
Komaba H; Shin J; Fukagawa M
Nephrol Dial Transplant; 2010 Feb; 25(2):638-41. PubMed ID: 19892751
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
12. Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?
Lomonte C; Vernaglione L; Chimienti D; Bruno A; Cocola S; Teutonico A; Cazzato F; Basile C
Clin J Am Soc Nephrol; 2008 May; 3(3):794-9. PubMed ID: 18322048
[TBL] [Abstract][Full Text] [Related]
13. [Hyperparathyroidism--new aspects].
Kruse A; Beige J
Ther Umsch; 2007 May; 64(5):265-9. PubMed ID: 17685085
[TBL] [Abstract][Full Text] [Related]
14. Effects of cinacalcet in renal transplant patients with hyperparathyroidism.
Courbebaisse M; Diet C; Timsit MO; Mamzer MF; Thervet E; Noel LH; Legendre C; Friedlander G; Martinez F; Prié D
Am J Nephrol; 2012; 35(4):341-8. PubMed ID: 22473131
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet: pharmacological and clinical aspects.
Messa P; Alfieri C; Brezzi B
Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1551-60. PubMed ID: 19040330
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
[TBL] [Abstract][Full Text] [Related]
19. Achieving therapeutic targets in the treatment of secondary hyperparathyroidism.
Cunningham J
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V9-14. PubMed ID: 15284354
[TBL] [Abstract][Full Text] [Related]
20. [Management of secondary hyperparathyroidism].
Cunningham J
Clin Calcium; 2005 Sep; 15 Suppl 1():217-24. PubMed ID: 16279027
[No Abstract] [Full Text] [Related]
[Next] [New Search]